

North America Tumor Ablation Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 120 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$3999.00
- Five User License \$5299.00
- Corporate License \$6299.00

Report description:

North America Tumor Ablation Market Report and Forecast 2024-2032

North America Tumor Ablation Market Outlook

The North America tumor ablation market size was valued at USD 0.71 billion in 2023, driven by the rising prevalence and incidence of cancer in the region. The market is expected to grow at a CAGR of 12.30% during the forecast period of 2024-2032, with the values likely to rise from USD 0.79 billion in 2024 to USD 2.01 billion by 2032.

Key Takeaways

- In March 2024, Medtronic plc announced FDA 501 (k) clearance for its bone tumor ablation system called OsteoCool 2.0 to treat benign bone tumors and painful bone metastases.
- The American Cancer Society estimated around 2,001,140 new cancer cases and 611,720 deaths caused by cancer in the United States in 2024.
- In September 2023, the United States Food and Drug Administration (FDA) approved ablation treatment planning and confirmation software, VisAble.IO, to facilitate image-guided ablation therapy.

North America Tumor Ablation Market Analysis

Tumor ablation is a minimally invasive technique in which interventional radiologists guide a needle-tipped catheter directly into a tumor, followed by applying extreme heat or cold to destroy or shrink the tumor. Imaging techniques are generally used to precisely find the tumor location. The ability of tumor ablation treatment to shrink tumors can increase the longevity of patients, relieve pain, and even in some cases, cure cancer. The technical success of the treatment and its minimally invasive nature is expected to drive the North America tumor ablation market demand in the coming years.

Cancer ranks as the second leading cause of mortality in the United States. American Cancer Society estimated around 2,001,140 new cancer cases and 611,720 deaths are projected to affect the United States population in 2024. The rising cancer burden directly impacts the demand for effective treatment approaches to tackle the mortality rate caused by the disease. Thus, the

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

growing prevalence of cancer is expected to positively influence the North America tumor ablation market share in the region. The market is witnessing a surge in approvals from health regulatory authorities such as the United States Food and Drug Administration (FDA). In March 2024, United States based Medtronic plc announced FDA 501 (k) clearance for its bone tumor ablation system called OsteoCool 2.0. The upgraded design of the radiofrequency ablation system allows efficient treatment of benign bone tumors and painful bone metastases. The device can use four internally cooled probes at the same time and delivers 20W per channel, with the company claiming it as the most powerful bone tumor ablation on the market. Further, the company plans to introduce the product in the United States market this year. The launch of such innovative ablation systems is likely to augment the North America tumor ablation market growth in the forecast period.

The market is witnessing technological innovation in the field of tumor ablation systems which are increasing treatment precision and improving patient outcomes. In September 2023, the United States Food and Drug Administration (FDA) granted approval to ablation treatment planning and confirmation software, VisAble.IO, developed by Techsomed, an Israeli-based medical device company. The software uses the company's artificial intelligence-driven technology called BioTrace and facilitates image-guided ablation therapy, offering various advantages such as three-dimensional visualization of the ablation target. The rising integration of artificial intelligence in tumor ablation treatment is expected to optimize patient care and fuel market growth.

Other factors that drive the market share include the rising investment from the public and private sectors, heightened public awareness regarding the benefits of the technique, and the expanding applications of tumor ablation systems.

North America Tumor Ablation Market Segmentation??

"North America Tumor Ablation Market Report and Forecast 2024-2032" offers a detailed analysis of the market based on the following segments:

Market Breakup by Technology

- Radiofrequency (RF)Ablation
- Microwave Ablation
- Cryoablation
- Irreversible Electroporation
- Others

Market Breakup by Mode of Treatment

- Surgical Ablation
- Laparoscopic Ablation
- Percutaneous Ablation
- Others

Market Breakup by Application

- Liver Cancer
- Lung Cancer
- Kidney Cancer
- Bone Metastasis
- Others

Market Breakup by End User

- Hospital and Clinics
- Specialty Centers
- Others

Market Breakup by Countries

- United States of America
- Canada

North America Tumor Ablation Market: Competitor Landscape

The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

analysis by the leading key players. The major companies in the market are as follows:

- Sonacare Medical
- Medtronic Plc
- EDAP TMS
- Angiodynamics
- Healthtronics, INC
- Johnson & Johnson
- Boston Scientific Corporation
- Misonix, INC
- Biotronik

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

-□What was the North America tumor ablation market value in 2023?

The market attained a value of about USD 0.71 billion in 2023 driven by the rising prevalence and incidence of cancer in the region.

-□What is the North America tumor ablation market forecast outlook for 2024-2032?

The market is anticipated to grow at a CAGR of 12.30% during the forecast period of 2024-2032, likely to reach a market value of USD 2.01 billion by 2032.

-□What are the major factors aiding the North America tumor ablation market demand?

Technological innovations in tumor ablation systems and the rising preference for minimally invasive techniques are fuelling the demand for the market.

-□What are the major North America tumor ablation market trends?

One of the significant trends in the market is the surge in approvals from health regulatory authorities such as the United States FDA. In March 2024, Medtronic plc announced 501 (k) clearance for its bone tumor ablation system called OsteoCool 2.0. The upgraded design of the radiofrequency ablation system allows efficient treatment of benign bone tumors and painful bone metastases.

-□What is the market segmentation based on technology?

Based on the technology, the market is segmented into radiofrequency (RF) ablation, microwave ablation, cryoablation, and irreversible electroporation, among others.

-□What is the market breakup by mode of treatment?

By mode of treatment, the market is divided into surgical ablation, laparoscopic ablation, and percutaneous ablation, among others.

-□What are the major end users of tumor ablation market in North America?

End users of the market are hospitals, clinics, and specialty centers, among others.

-□What are the applications of North America tumor ablation market?

Major application areas of tumor ablation include liver cancer, lung cancer, kidney cancer, and bone metastasis, among others.

-□What is the market segmentation by countries?

The market segmentation by countries includes the United States of America and Canada.

-□Who are the key players involved in the North America tumor ablation market?

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

The key players in the market are Sonacare Medical, Medtronic Plc, EDAP TMS, Angiodynamics, Healthtronics, INC, Johnson & Johnson, Boston Scientific Corporation, Misonix, INC, and Biotronik.

Meta description

The North America tumor ablation market size was valued at USD 0.71 billion in 2023 and it is anticipated to grow at a CAGR of 12.30% during the forecast period of 2024-2032.

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope
 - 1.4 Research Methodology
- 2 Executive Summary
- 3 North America Tumor Ablation Market Overview
 - 3.1 North America Tumor Ablation Market Historical Value (2017-2023)
 - 3.2 North America Tumor Ablation Market Forecast Value (2024-2032)
- 4 North America Tumor Ablation Market Landscape*
 - 4.1 North America Tumor Ablation: Developers Landscape
 - 4.1.1 Analysis by Year of Establishment
 - 4.1.2 Analysis by Company Size
 - 4.1.3 Analysis by Region
 - 4.2 North America Tumor Ablation: Product Landscape
 - 4.2.1 Analysis by Technology
 - 4.2.2 Analysis by Mode of Treatment
- 5 North America Tumor Ablation Market Dynamics
 - 5.1 Market Drivers and Constraints
 - 5.2 SWOT Analysis
 - 5.2.1 Strengths
 - 5.2.2 Weaknesses
 - 5.2.3 Opportunities
 - 5.2.4 Threats
 - 5.3 Porter's Five Forces Analysis
 - 5.3.1 Bargaining Power of Suppliers
 - 5.3.2 Bargaining Power of Buyers
 - 5.3.3 Threat of New Entrants
 - 5.3.4 Threat of Substitutes
 - 5.3.5 Degree of Rivalry
 - 5.4 Key Demand Indicators
 - 5.5 Key Price Indicators
 - 5.6 Industry Events, Initiatives, and Trends
 - 5.7 Value Chain Analysis
- 6 North America Tumor Ablation Market Segmentation (2017-2032)
 - 6.1 North America Tumor Ablation Market (2017-2032) by Technology
 - 6.1.1 Market Overview
 - 6.1.2 Radiofrequency (RF) Ablation
 - 6.1.3 Microwave Ablation
 - 6.1.4 Cryoablation

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 6.1.5 Irreversible Electroporation
- 6.1.6 Others
- 6.2 North America Tumor Ablation Market (2017-2032) by Mode of Treatment
 - 6.2.1 Market Overview
 - 6.2.2 Surgical Ablation
 - 6.2.3 Laparoscopic Ablation
 - 6.2.4 Percutaneous Ablation
 - 6.2.5 Others
- 6.3 North America Tumor Ablation Market (2017-2032) by Application
 - 6.3.1 Market Overview
 - 6.3.2 Liver Cancer
 - 6.3.3 Lung Cancer
 - 6.3.4 Kidney Cancer
 - 6.3.5 Bone Metastasis
 - 6.3.6 Others
- 6.4 North America Tumor Ablation Market (2017-2032) by End User
 - 6.4.1 Market Overview
 - 6.4.2 Hospital and Clinics
 - 6.4.3 Specialty Centers
 - 6.4.4 Others
- 6.5 North America Tumor Ablation Market (2017-2032) by Countries
 - 6.5.1 Market Overview
 - 6.5.2 United States of America
 - 6.5.3 Canada
- 7 United States of America Tumor Ablation Market (2017-2032)
 - 7.1 United States of America Tumor Ablation Market (2017-2032) by Technology
 - 7.1.1 Market Overview
 - 7.1.2 Radiofrequency (RF) Ablation
 - 7.1.3 Microwave Ablation
 - 7.1.4 Cryoablation
 - 7.1.5 Irreversible Electroporation
 - 7.1.6 Others
 - 7.2 United States of America Tumor Ablation Market (2017-2032) by Mode of Treatment
 - 7.2.1 Market Overview
 - 7.2.2 Surgical Ablation
 - 7.2.3 Laparoscopic Ablation
 - 7.2.4 Percutaneous Ablation
 - 7.2.5 Others
 - 7.3 United States of America Tumor Ablation Market (2017-2032) by Application
 - 7.3.1 Market Overview
 - 7.3.2 Liver Cancer
 - 7.3.3 Lung Cancer
 - 7.3.4 Kidney Cancer
 - 7.3.5 Bone Metastasis
 - 7.3.6 Others
 - 7.4 United States of America Tumor Ablation Market (2017-2032) by End User
 - 7.4.1 Market Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 7.4.2 Hospital and Clinics
- 7.4.3 Specialty Centers
- 7.4.4 Others
- 8 Canada Tumor Ablation Market (2017-2032)
 - 8.1 Canada Tumor Ablation Market (2017-2032) by Technology
 - 8.1.1 Market Overview
 - 8.1.2 Radiofrequency (RF)Ablation
 - 8.1.3 Microwave Ablation
 - 8.1.4 Cryoablation
 - 8.1.5 Irreversible Electroporation
 - 8.1.6 Others
 - 8.2 Canada Tumor Ablation Market (2017-2032) by Mode of Treatment
 - 8.2.1 Market Overview
 - 8.2.2 Surgical Ablation
 - 8.2.3 Laparoscopic Ablation
 - 8.2.4 Percutaneous Ablation
 - 8.2.5 Others
 - 8.3 Canada Tumor Ablation Market (2017-2032) by Application
 - 8.3.1 Market Overview
 - 8.3.2 Liver Cancer
 - 8.3.3 Lung Cancer
 - 8.3.4 Kidney Cancer
 - 8.3.5 Bone Metastasis
 - 8.3.6 Others
 - 8.4 Canada Tumor Ablation Market (2017-2032) by End User
 - 8.4.1 Market Overview
 - 8.4.2 Hospital and Clinics
 - 8.4.3 Specialty Centers
 - 8.4.4 Others
- 9 Regulatory Framework
- 10 Patent Analysis
 - 10.1 Analysis by Type of Patent
 - 10.2 Analysis by Publication year
 - 10.3 Analysis by Issuing Authority
 - 10.4 Analysis by Patent Age
 - 10.5 Analysis by CPC Analysis
 - 10.6 Analysis by Patent Valuation
 - 10.7 Analysis by Key Players
- 11 Funding and Investment Analysis
 - 11.1 Analysis by Funding Instances
 - 11.2 Analysis by Type of Funding
 - 11.3 Analysis by Funding Amount
 - 11.4 Analysis by Leading Players
 - 11.5 Analysis by Leading Investors
 - 11.6 Analysis by Geography
- 12 Partnership and Collaborations Analysis
 - 12.1 Analysis by Partnership Instances

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 12.2 Analysis by Type of Partnership
- 12.3 Analysis by Leading Players
- 12.4 Analysis by Geography
- 13 Supplier Landscape
 - 13.1 Market Share by Top 5 Companies
 - 13.2 Sonacare Medical
 - 13.2.1 Financial Analysis
 - 13.2.2 Product Portfolio
 - 13.2.3 Demographic Reach and Achievements
 - 13.2.4 Mergers and Acquisitions
 - 13.2.5 Certifications
 - 13.3 Medtronic Plc
 - 13.3.1 Financial Analysis
 - 13.3.2 Product Portfolio
 - 13.3.3 Demographic Reach and Achievements
 - 13.3.4 Mergers and Acquisitions
 - 13.3.5 Certifications
 - 13.4 EDAP TMS
 - 13.4.1 Financial Analysis
 - 13.4.2 Product Portfolio
 - 13.4.3 Demographic Reach and Achievements
 - 13.4.4 Mergers and Acquisitions
 - 13.4.5 Certifications
 - 13.5 Angiodynamics
 - 13.5.1 Financial Analysis
 - 13.5.2 Product Portfolio
 - 13.5.3 Demographic Reach and Achievements
 - 13.5.4 Mergers and Acquisitions
 - 13.5.5 Certifications
 - 13.6 Healthtronics, Inc.
 - 13.6.1 Financial Analysis
 - 13.6.2 Product Portfolio
 - 13.6.3 Demographic Reach and Achievements
 - 13.6.4 Mergers and Acquisitions
 - 13.6.5 Certifications
 - 13.7 Johnson & Johnson
 - 13.7.1 Financial Analysis
 - 13.7.2 Product Portfolio
 - 13.7.3 Demographic Reach and Achievements
 - 13.7.4 Mergers and Acquisitions
 - 13.7.5 Certifications
 - 13.8 Boston Scientific Corporation
 - 13.8.1 Financial Analysis
 - 13.8.2 Product Portfolio
 - 13.8.3 Demographic Reach and Achievements
 - 13.8.4 Mergers and Acquisitions
 - 13.8.5 Certifications

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.9 Misonix, INC
 - 13.9.1 Financial Analysis
 - 13.9.2 Product Portfolio
 - 13.9.3 Demographic Reach and Achievements
 - 13.9.4 Mergers and Acquisitions
 - 13.9.5 Certifications
- 13.10 Biotronik
 - 13.10.1 Financial Analysis
 - 13.10.2 Product Portfolio
 - 13.10.3 Demographic Reach and Achievements
 - 13.10.4 Mergers and Acquisitions
 - 13.10.5 Certifications
- 14 North America Tumor Ablation Market - Distribution Model (Additional Insight)
 - 14.1 Overview
 - 14.2 Potential Distributors
 - 14.3 Key Parameters for Distribution Partner Assessment
- 15 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 16 Company Competitiveness Analysis (Additional Insight)
 - 16.1 Very Small Companies
 - 16.2 Small Companies
 - 16.3 Mid-Sized Companies
 - 16.4 Large Companies
 - 16.5 Very Large Companies
- 17 Payment Methods (Additional Insight)
 - 17.1 Government Funded
 - 17.2 Private Insurance
 - 17.3 Out-of-Pocket

*Additional insights provided are customisable as per client requirements.

* The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.

North America Tumor Ablation Market Report and Forecast 2024-2032

Market Report | 2024-06-26 | 120 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

| Select license | License | Price |
|----------------|---------------------|-----------|
| | Single User License | \$3999.00 |
| | Five User License | \$5299.00 |
| | Corporate License | \$6299.00 |
| | | VAT |
| | | Total |

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

| | | | |
|---------------|----------------------|-------------------------------|---|
| Email* | <input type="text"/> | Phone* | <input type="text"/> |
| First Name* | <input type="text"/> | Last Name* | <input type="text"/> |
| Job title* | <input type="text"/> | | |
| Company Name* | <input type="text"/> | EU Vat / Tax ID / NIP number* | <input type="text"/> |
| Address* | <input type="text"/> | City* | <input type="text"/> |
| Zip Code* | <input type="text"/> | Country* | <input type="text"/> |
| | | Date | <input type="text" value="2025-05-10"/> |
| | | Signature | <input type="text"/> |

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com